IL7R and acute lymphoblastic leukemia: Decoding the signaling pathways selectively activated by oncogenic IL-7R, as compared to those induced by wild type IL-7R, will provide strong rationale for tailoring T-ALL (and B-ALL) therapies based on targetable IL-7R-related molecules that specifically eliminate leukemic cells, while preserving normal T-cell development and homeostasis.